Physician profile
James W Cullison
NPI 1194787408
$2,344.81
in general payments reported to CMS, 2019-2025
26 companies · $34.73 in 2025
The $34.73 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $292 · 2021: $632 · 2022: $350 · 2023: $386 · 2025: $34.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.95 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $714.32 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $177.16 | 2021 | |
| Abbvie INC. | $161.02 | 2019-2025 | |
| Axonics, INC. | $152.51 | 2020-2021 | |
| Neotract INC. | $102.34 | 2019 | |
| Janssen Biotech, INC. | $101.43 | 2019-2023 | Erleada |
| Boston Scientific Corporation | $88.20 | 2019-2023 | Rezum Generator, Spaceoar Vue System - 10ml |
| Medtronic USA, INC. | $82.71 | 2019-2020 | |
| Myovant Sciences INC. | $78.71 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $78.58 | 2019-2022 | |
| Caldera Medical, INC | $76.60 | 2022 | |
| Blue Earth Diagnostics | $69.31 | 2019-2022 | |
| Antares Pharma, INC. | $64.80 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $58.94 | 2023-2025 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $58.92 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $58.36 | 2019 | |
| Pfizer INC. | $42.17 | 2019-2022 | |
| Coloplast Corp | $39.80 | 2020-2021 | |
| Tolmar Pharmaceuticals, INC. | $23.19 | 2021 | |
| Lumenis, INC | $21.41 | 2021 | |
| Rochester Medical Corporation | $20.16 | 2021 | |
| Allergan, INC. | $20.15 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.12 | 2019 | |
| Travere Therapeutics, INC. | $15.11 | 2020-2022 | |
| Amgen INC. | $14.65 | 2019 | |
| Ambu INC. | $8.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cullison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.